AR098670A1 - Inhibidor de sglt1 - Google Patents
Inhibidor de sglt1Info
- Publication number
- AR098670A1 AR098670A1 ARP140104010A ARP140104010A AR098670A1 AR 098670 A1 AR098670 A1 AR 098670A1 AR P140104010 A ARP140104010 A AR P140104010A AR P140104010 A ARP140104010 A AR P140104010A AR 098670 A1 AR098670 A1 AR 098670A1
- Authority
- AR
- Argentina
- Prior art keywords
- sglt1 inhibitor
- sglt1
- inhibitor
- hyperglycemia
- hydrate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente se refiere a un compuesto de fórmula (1) o hidrato del mismo, útil en la prevención y tratamiento de la hiperglicemia y diabetes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361901488P | 2013-11-08 | 2013-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098670A1 true AR098670A1 (es) | 2016-06-08 |
Family
ID=51982747
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104010A AR098670A1 (es) | 2013-11-08 | 2014-10-24 | Inhibidor de sglt1 |
| ARP210103177A AR124083A2 (es) | 2013-11-08 | 2021-11-17 | Nuevo inhibidor de sglt1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103177A AR124083A2 (es) | 2013-11-08 | 2021-11-17 | Nuevo inhibidor de sglt1 |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9573970B2 (es) |
| EP (1) | EP3066108B1 (es) |
| JP (1) | JP6197113B2 (es) |
| KR (1) | KR101858881B1 (es) |
| CN (1) | CN105705509B (es) |
| AP (1) | AP2016009180A0 (es) |
| AR (2) | AR098670A1 (es) |
| AU (1) | AU2014347065B2 (es) |
| CA (1) | CA2925128C (es) |
| CL (1) | CL2016000791A1 (es) |
| CR (1) | CR20160165A (es) |
| CY (1) | CY1121096T1 (es) |
| DK (1) | DK3066108T3 (es) |
| DO (1) | DOP2016000067A (es) |
| EA (1) | EA028801B1 (es) |
| ES (1) | ES2703944T3 (es) |
| HR (1) | HRP20182061T1 (es) |
| IL (1) | IL244899B (es) |
| JO (1) | JO3485B1 (es) |
| LT (1) | LT3066108T (es) |
| MA (1) | MA39019A1 (es) |
| MX (1) | MX368174B (es) |
| MY (1) | MY192242A (es) |
| NZ (1) | NZ718118A (es) |
| PE (1) | PE20160884A1 (es) |
| PH (1) | PH12016500851B1 (es) |
| PL (1) | PL3066108T3 (es) |
| PT (1) | PT3066108T (es) |
| RS (1) | RS58050B1 (es) |
| SI (1) | SI3066108T1 (es) |
| SV (1) | SV2016005190A (es) |
| TN (1) | TN2016000112A1 (es) |
| TW (1) | TWI655198B (es) |
| UA (1) | UA118767C2 (es) |
| WO (1) | WO2015069541A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020523394A (ja) * | 2017-06-12 | 2020-08-06 | リグナメッド・エルエルシーＬｉｇｎａｍｅｄ，Ｌｌｃ | （ｓ，ｓ）−セコイソラリシレシノールジグルコシド及び（ｒ，ｒ）−セコイソラリシレシノールジグルコシドの製造方法 |
| CN110054657B (zh) * | 2018-01-18 | 2021-06-29 | 亚宝药业集团股份有限公司 | 吡喃葡萄糖取代的吡唑化合物及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK286600B6 (sk) | 1999-08-31 | 2009-02-05 | Kissei Pharmaceutical Co., Ltd | Glukopyranozyloxypyrazolové deriváty, farmaceutická zmes s ich obsahom a medziprodukty na ich výrobu |
| CA2438593C (en) | 2001-02-26 | 2010-09-21 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
| WO2002098893A1 (en) | 2001-05-30 | 2002-12-12 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
| ZA200501094B (en) * | 2002-08-08 | 2006-10-25 | Kissei Pharmaceutical | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
| MXPA05001549A (es) * | 2002-08-08 | 2005-05-05 | Kissei Pharmaceutical | Derivado de pirazol, composicion medicinal que lo contiene, su uso medicinal, e intermediario para su produccion. |
| JP2004137245A (ja) | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| DE102004028241B4 (de) | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
| EP2076503B1 (en) * | 2006-05-19 | 2013-07-17 | Taisho Pharmaceutical Co., Ltd | C-phenyl glycitol compound for the treatment of diabetes |
| KR101416561B1 (ko) | 2007-12-27 | 2014-07-08 | 깃세이 야쿠힌 고교 가부시키가이샤 | 피라졸 유도체의 모노세박산염 |
| CN102414191B (zh) | 2009-02-23 | 2014-04-16 | 大正制药株式会社 | 4-异丙苯基山梨醇化合物作为sglt1抑制剂 |
| AU2010302642A1 (en) * | 2009-10-02 | 2012-04-26 | Sanofi | Use of compounds with SGLT-1/SGLT-2 inhibitor activity for producing medicaments for treatment of bone diseases |
| US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| UA113086C2 (xx) * | 2012-05-10 | 2016-12-12 | Піразольні сполуки як інгібітори sglt1 |
-
2014
- 2014-10-24 AR ARP140104010A patent/AR098670A1/es not_active Application Discontinuation
- 2014-10-26 JO JOP/2014/0310A patent/JO3485B1/ar active
- 2014-10-27 TW TW103137067A patent/TWI655198B/zh active
- 2014-10-30 US US15/026,427 patent/US9573970B2/en active Active
- 2014-10-30 PE PE2016000546A patent/PE20160884A1/es unknown
- 2014-10-30 NZ NZ718118A patent/NZ718118A/en unknown
- 2014-10-30 EA EA201690749A patent/EA028801B1/ru not_active IP Right Cessation
- 2014-10-30 WO PCT/US2014/063161 patent/WO2015069541A1/en active Application Filing
- 2014-10-30 KR KR1020167011764A patent/KR101858881B1/ko active IP Right Grant
- 2014-10-30 CA CA2925128A patent/CA2925128C/en active Active
- 2014-10-30 TN TN2016000112A patent/TN2016000112A1/en unknown
- 2014-10-30 MA MA39019A patent/MA39019A1/fr unknown
- 2014-10-30 EP EP14802974.7A patent/EP3066108B1/en active Active
- 2014-10-30 JP JP2016526778A patent/JP6197113B2/ja active Active
- 2014-10-30 RS RS20181382A patent/RS58050B1/sr unknown
- 2014-10-30 SI SI201430941T patent/SI3066108T1/sl unknown
- 2014-10-30 PL PL14802974T patent/PL3066108T3/pl unknown
- 2014-10-30 AU AU2014347065A patent/AU2014347065B2/en active Active
- 2014-10-30 UA UAA201603973A patent/UA118767C2/uk unknown
- 2014-10-30 DK DK14802974.7T patent/DK3066108T3/da active
- 2014-10-30 AP AP2016009180A patent/AP2016009180A0/en unknown
- 2014-10-30 LT LTEP14802974.7T patent/LT3066108T/lt unknown
- 2014-10-30 ES ES14802974T patent/ES2703944T3/es active Active
- 2014-10-30 MY MYPI2016701635A patent/MY192242A/en unknown
- 2014-10-30 PT PT14802974T patent/PT3066108T/pt unknown
- 2014-10-30 CN CN201480060924.9A patent/CN105705509B/zh active Active
- 2014-10-30 MX MX2016005999A patent/MX368174B/es active IP Right Grant
-
2016
- 2016-03-17 DO DO2016000067A patent/DOP2016000067A/es unknown
- 2016-04-04 IL IL24489916A patent/IL244899B/en active IP Right Grant
- 2016-04-06 CL CL2016000791A patent/CL2016000791A1/es unknown
- 2016-04-06 CR CR20160165A patent/CR20160165A/es unknown
- 2016-05-03 SV SV2016005190A patent/SV2016005190A/es unknown
- 2016-05-06 PH PH12016500851A patent/PH12016500851B1/en unknown
-
2018
- 2018-12-06 HR HRP20182061TT patent/HRP20182061T1/hr unknown
- 2018-12-12 CY CY181101334T patent/CY1121096T1/el unknown
-
2021
- 2021-11-17 AR ARP210103177A patent/AR124083A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015010125A (es) | Derivados de piridazinona-amidas. | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| EA201591624A1 (ru) | Новые производные пиразола | |
| PH12015502665A1 (en) | Improvements in or relating to organic compounds | |
| CO2017003699A2 (es) | Compuesto heterocíclico | |
| PH12017501071A1 (en) | Dihydropyrimidin-2-one compounds and medical use thereof | |
| BR112017008481A2 (pt) | composto antimicótico | |
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| BR112016012248A2 (pt) | método de tratamento de nefropatia | |
| PH12016501183A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| AR124083A2 (es) | Nuevo inhibidor de sglt1 | |
| MX363458B (es) | Nuevos derivados de tetrazolona. | |
| PH12016501184A1 (en) | Novel compound for treatment of severe hypoglycemia | |
| ECSP16024798A (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
| CL2016001054A1 (es) | Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma | |
| EA201600134A1 (ru) | Воласертиб в комбинации с азацитидином для лечения острого миелоидного лейкоза и миелодиспластического синдрома | |
| NZ717880A (en) | Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors | |
| UY35165A (es) | Método profiláctico o terapéutico para el síndrome de sjogren | |
| WO2014180882A3 (en) | Treatment of brain metastasis from cancer | |
| EA201792502A1 (ru) | Кабазитаксел и его применение для лечения рака | |
| CY1117740T1 (el) | Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης | |
| MX366815B (es) | Polioles, su preparación y su uso. | |
| MX2015017136A (es) | Composicion para la administracion oral de magnesio, en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma. | |
| UA87254U (ru) | Соединение 1,1-диэтилкарбокси-2-метокси-2-трифторметилэтилен с потенциальными физиологическими свойствами | |
| UA89447U (ru) | Соединение 1,1-диэтилкарбокси-2-хлор-2-трифторметилэтилен с потенциальными физиологическими свойствами |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |